Join us as we go over our top stories from the week:
Advanced Gene Therapy TR002 Moves to Phase III Clinical Trial for Mesothelioma.
FirstHealth Makes History Enrolling the First Patient in Immunotherapy Clinical Trial Addressing Cervical Cancer.
San Francisco-Based, Infectious Disease-Focused Vir Biotechnology Now Files for IPO.
Large Payer Cigna to Fully Cover Multi-Million Dollar Gene Therapies.
California’s Central Valley Center of German-Originated $28M Biotechnology Firm Investment.
UCLA Investigator Leads Small Clinical Trial that Actually Reverses Aging Process by 2.5 Years on Average.
Thomas Jefferson University-based Research: Clinical Trials Under Siege in America.
Genentech Reports Results From Phase 3 BLOCKSTONE Trial; Xofluza Reduces Flu Threat by 86% Following Exposure.
Center for Psychedelic Research Opens at Johns Hopkins Medicine.
Northwestern Medicine’s ‘Successful’ Immunotherapy and Autoimmune Disease Research Program to Shut its’ Doors.
Drug Makers Responding to Price Pressures and Start Dropping Insulin Costs.
Penn PACE: Medicine & Radiology Receive $8.9M & Build a Center of Excellence Dedicated to Opioid Use Disorder Researc...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).